Vycor Medical, Inc.
VYCO
$0.07
$0.00-0.29%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.06% | -8.41% | 31.44% | 22.18% | 29.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.06% | -8.41% | 31.44% | 22.18% | 29.50% |
| Cost of Revenue | 7.20% | 41.00% | 68.21% | 130.40% | 110.27% |
| Gross Profit | 4.66% | -15.60% | 27.62% | 11.91% | 19.50% |
| SG&A Expenses | -10.07% | 0.14% | 10.08% | 2.13% | 19.04% |
| Depreciation & Amortization | -6.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.13% | 4.01% | 13.08% | 14.12% | 29.64% |
| Operating Income | 457.81% | -289.12% | 191.45% | 215.43% | -34.74% |
| Income Before Tax | 152.21% | -831.34% | 108.36% | 357.00% | -26.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 152.21% | -831.34% | 108.36% | 357.00% | -26.23% |
| Earnings from Discontinued Operations | -- | -200.00% | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 152.07% | -835.82% | 108.19% | 339.00% | -26.14% |
| EBIT | 457.81% | -289.12% | 191.45% | 215.43% | -34.74% |
| EBITDA | 1,763.64% | -156.35% | 347.42% | 107.52% | -45.90% |
| EPS Basic | 28.33% | -850.00% | 29.85% | 333.33% | -1.69% |
| Normalized Basic EPS | 157.14% | -1,100.00% | 109.09% | 350.00% | -16.67% |
| EPS Diluted | 28.33% | -850.00% | 29.85% | 300.00% | -1.69% |
| Normalized Diluted EPS | 157.14% | -1,100.00% | 109.09% | 300.00% | -16.67% |
| Average Basic Shares Outstanding | 0.00% | -0.01% | 1.43% | 2.28% | 2.28% |
| Average Diluted Shares Outstanding | 0.00% | -0.01% | 1.43% | 18.51% | 2.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |